Literature DB >> 11355911

The pathology of epithelial pre-malignancy of the gastrointestinal tract.

M Guindi1, R H Riddell.   

Abstract

This chapter deals with pre-malignant epithelial lesions of the gastrointestinal tract that have the potential to become cancers. Pre-malignant lesions are divided into two types: those characterized by dysplastic mucosa and those without dysplasia. Examples of the two types are present in the oesophagus, stomach and intestine. In the oesophagus, dysplasia of the squamous epithelium is a precursor to squamous carcinoma. There are differences in interpretation between Western and Japanese pathologists in the diagnosis of oesophageal squamous lesions. Dysplasia in Barrett's oesophagus is regarded as a precursor of adenocarcinoma. The goal of endoscopic surveillance in Barrett's mucosa is the detection of high-grade dysplasia. There are several problems with our current knowledge of high-grade dysplasia and controversies regarding its management. There are differences in the interpretation of biopsies of gastric epithelial dysplasia between Japanese and Western pathologists. In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas. The most significant predictor of the risk of malignancy in patients with inflammatory bowel disease is the presence of dysplasia in colonic biopsies. Because of the similarity of neoplasia throughout the gastrointestinal tract, there have been attempts to unify its classification, terminology and diagnostic criteria internationally, the most recently proposed modified classification of gastrointestinal neoplasia being the Vienna classification. Dysplasia of the columnar mucosa has a similar appearance in Barrett's oesophagus, the stomach and the colon. Criteria for its histological diagnosis and grading are reviewed, with an emphasis on areas of diagnostic difficulty such as interobserver variation, and discrepancies between Western and Japanese pathologists. Implication of the presence of dysplasia that are specific to each organ site are discussed, highlighting weaknesses and controversies in current knowledge. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11355911     DOI: 10.1053/bega.2001.0169

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  8 in total

1.  Dual infection with Helicobacter bilis and Helicobacter hepaticus in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia.

Authors:  Lillian Maggio-Price; Helle Bielefeldt-Ohmann; Piper Treuting; Brian M Iritani; Weiping Zeng; Andrea Nicks; Mark Tsang; Donna Shows; Phil Morrissey; Joanne L Viney
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

2.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

3.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

4.  Transgelin Inhibits the Malignant Progression of Esophageal Squamous Cell Carcinomas by Regulating Epithelial-Mesenchymal Transition.

Authors:  Boli Yang; Qiuyu Chen; Changshan Wan; Siyuan Sun; Lanping Zhu; Zhizhong Zhao; Weilong Zhong; Bangmang Wang
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 5.738

5.  miR-25 is upregulated before the occurrence of esophageal squamous cell carcinoma.

Authors:  Yaxu Jia; Heng Lu; Cheng Wang; Junjun Wang; Chenyu Zhang; Fangyu Wang; Chunni Zhang
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

6.  Protein kinase Cbeta is an effective target for chemoprevention of colon cancer.

Authors:  Alan P Fields; Shelly R Calcagno; Murli Krishna; Sofija Rak; Michael Leitges; Nicole R Murray
Journal:  Cancer Res       Date:  2009-02-15       Impact factor: 12.701

7.  A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia.

Authors:  M Dinis-Ribeiro; C Lopes; A da Costa-Pereira; M Guilherme; J Barbosa; H Lomba-Viana; R Silva; L Moreira-Dias
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

8.  A new practical classification of desmoplastic reaction in endoscopic forceps biopsy of colorectal cancer.

Authors:  Haiyan Jing; Liang Shang; Shulei Zhao; Zhigang Yao; Beibei Lv; Xiaolong Zhu
Journal:  Histol Histopathol       Date:  2021-06-15       Impact factor: 2.303

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.